New Approach Could Overcome PI3K Inhibitor Resistance
Lab studies show that targeting the AR-UBE2C axis may help sensitize certain breast and prostate cancer cells to treatment.
Updated on Oct. 16, 2026 in Cancer
Researchers have identified a new mechanism that allows certain breast and prostate cancers to resist PI3K inhibitor treatments. The findings suggest that targeting the AR-UBE2C axis could restore the effectiveness of these therapies in preclinical models.
Why it matters
Understanding how cancer cells develop resistance to common treatments is essential for improving long-term outcomes. This study reveals a specific pathway that blocks drug-induced cell death, providing a potential strategy to sensitize resistant tumor cells.
This preclinical laboratory study identified that high levels of the UBE2C protein suppress cell death in cancer cells. The research demonstrated that silencing the androgen receptor, or using Enzalutamide, effectively restores susceptibility to the PI3K inhibitor Compound 8 in resistant cells.
The players
Enzalutamide
An anti-androgen medication used in the treatment of prostate cancer.
The details
The study centers on the AR-UBE2C axis, where high levels of androgen receptors lead to increased UBE2C protein expression. This protein prevents the cancer cell from initiating autophagy-associated cell death, effectively allowing the tumor to bypass the effects of PI3K inhibitors. By using Enzalutamide to block this receptor, researchers were able to reactivate the cell death process, sensitizing the tumors to the fluorinated isoflavone derivative Compound 8.
Timeline
October 16, 2026: Findings were published.
Health Landscape
PI3K inhibitors represent a significant class of targeted cancer therapies designed to stop tumor cell proliferation. This research aligns with the broader oncology trend of identifying specific molecular pathways that cause intrinsic drug resistance to improve current standard-of-care treatments.
This research provides a deeper understanding of how certain cancers evade treatment, but it is currently limited to laboratory models. Patients undergoing cancer treatment should discuss their specific diagnosis and therapeutic options, including potential clinical trial participation, with their oncologist.
The takeaway
Targeting the AR-UBE2C axis may eventually offer a way to overcome resistance to PI3K inhibitor therapies in specific breast and prostate cancers. If you are managing a cancer diagnosis, speak with your care team about how current treatment resistance is monitored and what emerging therapies might be relevant to your clinical situation.
Further reading
Learn more about the latest research in Cancer.
Source note: This article includes information reported by Nature.
